Health ❯ Vaccines ❯ Covid-19 ❯ Moderna

mNEXSPIKE

FDA Approves Moderna’s mNEXSPIKE for High-Risk Populations

Rollout is planned for the 2025-26 respiratory virus season under a new policy limiting COVID-19 boosters to high-risk groups.

FDA Approves Moderna’s mNEXSPIKE for Seniors and High-Risk Adults as CDC Drops Recommendations for Healthy Children and Pregnant Women